Sirolimus - Metabolism
Research News and Information

Sunday, November 22, 2009

Systematic gene expression profile of hypothalamus in calorie-restricted mice implicates the involvement of mTOR signaling in neuroprotective activity.

28 Jul 2009 Calorie restriction (CR) delays aging and onset of age-related diseases in a variety of organisms from yeast to mammals. However, the molecular mechanism underlying the CR effect remains to be elucidated. It is well known that the hypothalamus is an ... Read more...

m(en)TOR(ing) differentiating T helper cells.

17 Jun 2009 The decision of naive Th cells to assume the fate of effector or regulator Th cells heavily influences the outcome of adaptive immune responses. In this issue of Immunity, Delgoffe et al. (2009) use genetic approaches and demonstrate that mTOR ... Read more...

Biphasic activation of the mTOR pathway in the gustatory cortex is correlated with and necessary for taste learning.

8 Jun 2009 Different forms of memories and synaptic plasticity require synthesis of new proteins at the time of acquisition or immediately after. We are interested in the role of translation regulation in the cortex, the brain structure assumed to store ... Read more...

Latest indexed articles for 'Sirolimus - Metabolism'

These are the very latest articles for this heading:

• Systematic gene expression profile of hypothalamus in calorie-restricted mice implicates the involvement of mTOR signaling in neuroprotective activity. 28 Jul 2009
• New mTOR inhibitor for renal cell cancer. 29 Jun 2009
• m(en)TOR(ing) differentiating T helper cells. 17 Jun 2009
• Biphasic activation of the mTOR pathway in the gustatory cortex is correlated with and necessary for taste learning. 8 Jun 2009
• Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. 30 May 2009
• XAP2 inhibits glucocorticoid receptor activity in mammalian cells. 14 Apr 2009
• mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. 30 Mar 2009
• Generation of high-yield rapamycin-producing strains through protoplasts-related techniques. 2 Mar 2009
• Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. 16 Feb 2009
• Evaluation of mTOR function by a gain-of-function approach. 16 Feb 2009
• T cell dependence on mTOR signaling. 10 Feb 2009
• Metallothionein: a new soldier in the fight against chronic renal hypoxia? 30 Jan 2009
• Activating transcription factor 4 and CCAAT/enhancer-binding protein-beta negatively regulate the mammalian target of rapamycin via Redd1 expression in response to oxidative and endoplasmic reticulum stress. 25 Jan 2009
• Participation of mammalian target of rapamycin complex 1 in Toll-like receptor 2- and 4-induced neutrophil activation and acute lung injury. 6 Jan 2009
• Ligand-regulated peptide aptamers. 30 Dec 2008
• Photodynamic therapy targets the mTOR signaling network in vitro and in vivo. 30 Dec 2008
• PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. 28 Dec 2008
• mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). 13 Dec 2008
• Insulin-like growth factor stimulation increases radiosensitivity of a pancreatic cancer cell line through endoplasmic reticulum stress under hypoxic conditions. 15 Nov 2008
• Zebrafish Tsc1 reveals functional interactions between the cilium and the TOR pathway. 11 Nov 2008

See a longer list of these articles.

Technical information about 'Sirolimus'

Definition: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.

Registry Number: 53123-88-9

Descriptor UI: D020123

Alternative terms: Sirolimus; Rapamycin; I-2190A; I 2190A; I2190A; AY 22-989; AY 22 989; AY 22989; Rapamune; Wyeth Brand of Sirolimus;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antibiotics, Antineoplastic; Antifungal Agents; Immunosuppressive Agents; Anti-Bacterial Agents;

Tree Number: D02.540.505.760; D04.345.349.760;

History Note: 99; use SIROLIMUS (NM) 1980-97